Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etelcalcetide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.44 |
| ▸ | NPY4R | P50391 | 11/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.44 |
| ▸ | NPY1R | P25929 | 8/20 | 0.44 |
| ▸ | NPY2R | P49146 | 5/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etelcalcetide SCHEMBL20869502 | 1.00 | SIRT5 (0.44) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| Etelcalcetide SCHEMBL20869503 | 1.00 | SIRT5 (0.44) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| Etelcalcetide SCHEMBL22578458 | 0.99 | SIRT5 (0.43) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| Hydrochloric Acid SCHEMBL28425407 | 0.99 | SIRT5 (0.43) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| Etelcalcetide SCHEMBL22578464 | 0.99 | SIRT5 (0.43) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL24991307 | 0.95 | SIRT5 (0.44) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL19912225 | 0.93 | NPY4R (0.40) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| Etelcalcetide SCHEMBL22578460 | 0.93 | SIRT5 (0.49) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL16690663 | 0.87 | NPY4R (0.48) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL16690636 | 0.87 | NPY4R (0.48) | SIRT5NPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 562 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-20260102414-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | SANIFIT THERAPEUTICS S A (ES) | 2026-04-16 | — | — | US | claimed |
| EP-4719381-A1 | LIGAND-POLAR DRUG CONJUGATES | Tripartite Therapeutics Inc. (TW) | 2026-04-08 | — | — | EP | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| US-20250352609-A1 | Methods For Treating Alzheimer's Disease or Dementia Using A Calcilytic And A Calcimimetic | US GOV VETERANS AFFAIRS (US) | 2025-11-20 | — | — | US | claimed |
| WO-2025227105-A1 | CLEAVABLE LINKERS WITH TUNABLE HALF-LIVES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-10-30 | — | — | WO | claimed |
| US-20250295676-A1 | INOSITOL PHOSPHATE COMPOUNDS FOR USE IN TREATING, INHIBITING THE PROGRESSION, OR PREVENTING CARDIOVASCULAR CALCIFICATION | VIFOR (INTERNATIONAL) LTD. (CH) | 2025-09-25 | — | — | US | claimed |
| EP-4601623-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2025-08-20 | — | — | EP | claimed |
| WO-2025128821-A1 | COMPOSITIONS AND METHODS FOR ADP-RIBOSYLATION FACTOR MOLECULAR TRAFFICKING | JUVENA THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| CN-115181158-B | FMOC group cleavage method | 北京费森尤斯卡比医药有限公司 | 2025-06-13 | — | — | CN | claimed |
| US-11377474-B2 | Method for preparing AMG 416 (etelcalcetide) | AMGEN INC. (US) | 2022-07-05 | — | — | US | claimed |
| US-20220185842-A1 | AMINO DEPROTECTION USING 3-(DIETHYLAMINO)PROPYLAMINE | Alma Mater Studiorum - Università di Bologna (IT) | 2022-06-16 | — | — | US | claimed |
| EP-4011901-A1 | METHOD FOR THE FMOC GROUP CLEAVAGE | Fresenius Kabi iPSUM S.r.l. (IT) | 2022-06-15 | — | — | EP | claimed |
| WO-2022119840-A1 | METHODS AND COMPOSITIONS FOR CANNABINOID-BASED THERAPEUTICS | OJAI ENERGETICS PBC (US) | 2022-06-09 | — | — | WO | claimed |
| CN-112175042-B | Method for synthesizing Etelcalcetide | 深圳翰宇药业股份有限公司 | 2022-05-31 | — | — | CN | claimed |
| CN-114524860-A | Synthesis method and application of Etelcalcetide | 深圳翰宇药业股份有限公司 | 2022-05-24 | — | — | CN | claimed |
| WO-2022104212-A1 | METHODS FOR DECREASING MORTALITY RISK AND IMPROVING HEALTH | AMGEN INC. (US) | 2022-05-19 | — | — | WO | claimed |
| CN-114376970-A | Stable liquid formulations of etelcalcitide (AMG 416) | 美国安进公司 | 2022-04-22 | — | — | CN | claimed |
| WO-2022044030-A1 | AN IMPROVED PROCESS FOR FMOC SYNTHESIS OF ETELCALCETIDE | USV PRIVATE LIMITED (IN) | 2022-03-03 | — | — | WO | claimed |
| WO-2022034545-A1 | ETELCALCETIDE FORMULATIONS FOR PARENTERAL USE | AUROBINDO PHARMA LIMITED (IN) | 2022-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295676-A1 | INOSITOL PHOSPHATE COMPOUNDS FOR USE IN TREATING, INHIBITING THE PROGRESSION, OR PREVENTING CARDIOVASCULAR CALCIFICATION | PPIP5K2, INPP5B, IP6K3 | SIRT5 213/4885NPY4R 4794/4885NPY5R 4193/4885 |
| US-12533321-B2 | Polypeptide formulations for oral delivery | PTMS, IAPP, IGF1R | SIRT5 913/4885NPY4R 67/4885NPY5R 233/4885 |
| US-20220185842-A1 | AMINO DEPROTECTION USING 3-(DIETHYLAMINO)PROPYLAMINE | PEPD, ANPEP, DNPEP | SIRT5 427/4885NPY4R 297/4885NPY5R 176/4885 |
| US-20260102414-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | ATP6V1B1, IP6K3, IP6K1 | SIRT5 2154/4885NPY4R 2297/4885NPY5R 1313/4885 |
| US-11377474-B2 | Method for preparing AMG 416 (etelcalcetide) | CYP24A1, PTH1R, MME | SIRT5 2589/4885NPY4R 373/4885NPY5R 902/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | SIRT5 3477/4885NPY4R 6/4885NPY5R 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.